About US
Contact us
-
AstraZeneca, Pfizer, Novartis and more lose out in China's latest round of drug price cutsIn another abysmal day for large pharma companies’ off-patent drugs, generics makers have once again offered hefty discounts to win large tender offers in China, elbowing out original developers.2022/8/9
-
Eying Pfizer, Alnylam's high-stakes Onpattro heart trial delivers partial win but misses on key outcomes goalAfter an investigational BridgeBio drug surprisingly failed a clinical trial that would have set up a fight against Pfizer in a rare heart condition, investors have been worrying about Alnylam becaus2022/8/4
-
Teva runs into Adderall supply hitch as ADHD diagnoses mount, pledges prompt restockingAmid a national spike in attention-deficit/hyperactivity disorder diagnoses, one of the U.S.’ top providers of a popular ADHD medication has run into supply problems. Both 20-mg and 30-mg2022/8/4
-
Amgen partners with Fosun to bring Otezla, Parsabiv to patients in ChinaIn an effort to grow its presence in China, U.S. biotech giant Amgen has partnered with China’s Fosun Pharma to bring Otezla and Parsabiv to patients in the country. Amgen China will out-2022/8/1
-
AstraZeneca to build production facility in China for COPD inhaler BreztriAstraZeneca plans to build a manufacturing facility in Qingdao, China, to produce its Breztri aerosol inhalant COPD treatment, which was recently added to the country’s National Reimbursement Drug Li2022/8/1
-
Ginkgo to acquire Zymergen for $300mGinkgo Bioworks hassigneda definitive agreement for the acquisition of biotechnology company Zymergen in an all-stock deal worth nearly $300m. According to the agreement, 5.25% of the pro forma merge2022/7/27
-
FDA accepts BLA for Sandoz’s proposed biosimilar natalizumabThe US Food and Drug Administration (FDA) hasacceptedthe biologics licence application (BLA) ofNovartissubsidiary Sandoz for natalizumab, a proposed first-ever multiple sclerosis (MS) biosimilar to r2022/7/27
-
PhexTour 2022- Jinan station successfully concluded.PhexTour Pharmaceutical PreparationTechnology Application Seminar - Jinan station, on July 22, 2022 in JinanGaoxin Zhixuan Holiday successfully concluded. In view of the impact of the epidemic, thec2022/7/22
-
Amgen partners with Fosun to bring Otezla, Parsabiv to patients in ChinaIn an effort to grow its presence in China, U.S. biotech giant Amgen has partnered with China’s Fosun Pharma to bring Otezla and Parsabiv to patients in the country. Amgen China will out-licens2022/7/20
-
WuXi debuts another high-potency API production facility in ChinaWuxi STA, a subsidiary of WuXi AppTec, continued its manufacturing expansion march with theopeningof another high-potency active pharmaceutical ingredient (HPAPI) production facility in China.2022/7/20